dba

vast.png

                                          

 Home    Literature   Product Citations

 

 

PD-1/PD-L1- Immune Checkpoint Blockade for Cancer

Immunotherapy

Programmed death 1 (PD-1) is an immune checkpoint receptor expressed on several immune cells, particularly cytotoxic T cells. PD-1 has a prominent role in modulating T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC). The effects of interaction of PD1 with PD-L1 and PD-L2 are inhibition of T-cell proliferation, survival and cytokine production, hence escaping immune responses and preventing autoimmunity. Blocking interaction between PD1 and its ligand is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. BioVision offers a comprehensive collection of products, including proteins, antibodies, ELISA kits and more to support programmed cell death research.

 

 

Key Features:

  • High Purity: greater than 90% by SDS-PAGE and SEC-HPLC
  • High Activity: validated in functional ELISA
  • Low Endotoxin: less than 1EU/µg
  • Human CellExp™ expressed in HEK293 cells
  • Comprehensive collection: Fc-tagged, His-tagged, Biotinylated and/or tag free

 discover all2

 

Click here to see our Immunotherapy:Targeting ImmuneCheckpoints flyer

08212018

Fig.1. Biological activity: Immobilized Human PD-L1, His Tag at 5 µg/mL (100 µL/well) can bind Human PD-1, His Tag with a linear range of 0.15-1.25 µg/mL
Fig. 2. SDS-PAGE (4-20%) of Recombinant Human PD-1: 2 µg Human PD-1 recombinant protein loaded under reducing conditions and stained with Coomassie Blue.

 

 

Richiedi un'offerta

DBA-ITALIA Srl
Via Umbria 10
20090 Segrate (Milano)

Tel. +39 02-26922300
Fax +39 02-26926058
Fax +39 02-26923535




If you no longer wish to receive these announcements click here